September 20, 2023
Press releases
Latest news
August 03, 2023
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
Read more
July 31, 2023
Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Read more
July 27, 2023
Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update
Read more
July 12, 2023
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
Read more
July 06, 2023
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Read more
June 21, 2023
Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts
Read more
Displaying 1 - 10 of 10